Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 2, 1997, Pages 84-89

  Kirby, R ^a   Jardin, A ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Alpha 1 adrenergic antagonist; Benign prostatic hyperplasia; Doxazosin; Elderly

Indexed keywords

EID: 3142605637     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500211     Document Type: Article

References (24)

1. Chute CG et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-89.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 38: 469-471.
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-179.
4. Boyle P, Napalkov P. Epidemiology of benign prostatic hyperplasia. Current perspectives. Eur Urol 1996; 29 (suppl): 7-11.
5. Calais da Silva F et al. Hypertension in men with symptoms of lower urinary tract dysfunction. J Urol 1996; 155: 630A (Abstract 1275).
6. Christensen MM et al. Doxazosin in short-term treatment of prostatic obstruction - a double-blind placebo-controlled study. Scand J Urol Nephrol 1993; 27: 39-44.
7. Janknegt RA, Chapple CR, for the Doxazosin Study Groups. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993; 24: 319-326.
8. Chapple CR et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-56.
9. Holme JB et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 1994; 28: 77-82.
10. Fawzy A et al, for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-109.
11. Gillenwater JYet al, for the Multicenter Group. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115.
12. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in the treatment of hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
13. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183.
14. Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension Meeting. J Hypertens 1993; 11: 905-918.
15. Cox DA, Leader JP, Milson JA, Singleton W. The antihypertensive effects of doxazosin: a clinical overview. Br J Clin Pharmacol 1986; 21: 83S-90S.
16. Langdon CG. Doxazosin in hypertension: results of a general practice study in 4809 patients. Er J Clin Pract 1994; 48: 293-298.
17. Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized parallel study with a three-year follow-up. Am Heart J 1991; 121: 280-285.
18. Lepor H. Long-term efficacy and safety of doxazosin for the treatment of benign prostatic hyperplasia (suppl 273A), Proceedings of the AUA, April 1995; 153 Abstract 180.
19. Lepor H et al. Doxazosin in benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525-530.
20. Kaplan SA. Efficacy and safety of doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urol 1995; 46: 512-517.
21. Pickering TG, Levenstein M, Walmsley P, for the Hypertension and Lipid Trial Study Group. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and the presence of white coat hypertension. Results of the HALT study. Am J Hypertension 1994; 7: 848-852.
22. Kirby RS. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. Br J Clin Pract Symp Suppl 1994; 74: 23-28.
23. Kirby RS et al. Prazosin in the treatment of prostatic obstruction. A placebo controlled study. Br J Urol 1987; 60: 136-142.
24. Vincent J, Meredith PA, Elliott HL, Reid JL. The pharmacokinetics of doxazosin in elderly normotensives. Br J Clin Pharmacol 1986; 21: 521-524.